[HTML][HTML] Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
L Cheng, A Lopez-Beltran, F Massari, GT MacLennan… - Modern Pathology, 2018 - Elsevier
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
[PDF][PDF] Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
L Cheng, A Lopez-Beltran… - Modern …, 2018 - scholarworks.indianapolis.iu.edu
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
[HTML][HTML] Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
L Cheng, A Lopez-Beltran, F Massari… - Modern …, 2018 - nature.com
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
Molecular testing for BRAF mutations to inform melanoma treatment decisions: A move toward precision medicine
L Cheng, A Lopez-Beltran, F Massari… - MODERN …, 2018 - cris.unibo.it
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
[HTML][HTML] Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
L Cheng, A Lopez-Beltran, F Massari… - Modern …, 2018 - modernpathology.org
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
L Cheng, A Lopez-Beltran, F Massari… - … : an official journal …, 2018 - pubmed.ncbi.nlm.nih.gov
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
[PDF][PDF] Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
L Cheng, A Lopez-Beltran, F Massari, GT MacLennan… - 2018 - scholarworks.iupui.edu
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine.
L Cheng, A Lopez-Beltran, F Massari… - Modern Pathology: an …, 2017 - europepmc.org
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
[HTML][HTML] Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
L Cheng, A Lopez-Beltran, F Massari… - Modern …, 2018 - ncbi.nlm.nih.gov
Approximately one-half of advanced (unresectable or metastatic) melanomas harbor a
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
mutation in the BRAF gene, with V600E being the most common mutation. Targeted therapy …
[引用][C] Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
L Cheng, A Lopez-Beltran, F Massari… - Modern Pathology, 2018 - cir.nii.ac.jp
Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move
toward precision medicine | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …
toward precision medicine | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ …